These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7400367)

  • 1. Clinical pharmacology studies with indobufen (K 3920): inhibitor of platelet aggregation.
    Vinazzer H; Fuccella LM
    J Clin Pharmacol; 1980; 20(5-6 Pt 1):316-25. PubMed ID: 7400367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical-experimental studies on the inhibition of thrombocyte function with acetylsalicylic acid and with indobufen].
    Vinazzer H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):783-96. PubMed ID: 94870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of platelet aggregation in man by indobufen (K 3920).
    Vittoria A; Laghi Pasini F; Messa GL; Di Perri T; Corvi G; Fuccella LM
    J Int Med Res; 1981; 9(1):12-7. PubMed ID: 7202826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-thromboglobulin and platelet factor 4 plasma levels during haemodialysis: effect of indobufen.
    Pogliani EM; Colombi M; Cristoforetti G; Valenti G; Miradoli R; Buccianti G
    Pharmatherapeutica; 1982; 3(2):127-32. PubMed ID: 6179101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulant Activities of Indobufen, an Antiplatelet Drug.
    Liu J; Xu D; Xia N; Hou K; Chen S; Wang Y; Li Y
    Molecules; 2018 Jun; 23(6):. PubMed ID: 29914049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic, bioavailability and pharmacodynamic study of indobufen (K 3920), an inhibitor of platelet aggregation, after a single dose in man.
    Fuccella LM; Corvi G; Moro E; Pogliani E; Tamassia V; Tosolini G
    Eur J Clin Pharmacol; 1979 Jun; 15(5):323-7. PubMed ID: 456403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different patterns of inhibition of adrenaline-induced platelet aggregation and kinetics in vivo by acetylsalicylic acid and indobufen.
    Fortunato JS; Pinheiro MJ; Monteiro MC; Rodrigues MA; Amaral I
    J Int Med Res; 1991; 19(4):305-17. PubMed ID: 1916004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of indobufen on occlusion of arteriovenous fistulas and some platelet activity in intermittent peritoneal dialysis patients.
    Dmoszyńska A; Janicki K; Janicka L; Przesmycki K; Sokołowska B; Walter-Croneck A
    Pol J Pharmacol; 1996; 48(3):327-9. PubMed ID: 9112671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific inhibition of 40 K protein phosphorylation in platelet by a new antithrombotic agent, d-indobufen.
    Mamiya S; Hagiwara M; Ishikawa T; Hidaka H
    Thromb Res; 1989 Jun; 54(5):447-56. PubMed ID: 2505401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and ex vivo effects of indobufen on human platelet aggregation, the release reaction and thromboxane B2 production.
    Cattaneo M; Bevilacqua C; Lecchi A; Mannucci PM
    Haemostasis; 1987; 17(5):293-300. PubMed ID: 3666587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary human pharmacology studies on the inhibition of platelet aggregation by indobufen (K 3920).
    Pogliani E; Corvi G; Mandelli V; Fuccella LM
    Haematologica; 1981 Apr; 66(2):160-70. PubMed ID: 6115794
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of spontaneous platelet aggregation and adhesion by indobufen (K 3920). A randomized, double-blind crossover study on platelet, coagulation and fibrinolysis function tests.
    Nenci GG; Berrettini M; Iadevaia V; Parise P; Ballatori E
    Pharmatherapeutica; 1982; 3(3):188-94. PubMed ID: 7134226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indobufen treatment in type IIA hypercholesterolemic subjects: effects on platelet function and malondialdehyde production.
    Tremoli E; Maderna P; Sirtori M; Colli S; Corvi G; Sirtori CR
    Pharmacol Res Commun; 1981 Oct; 13(9):847-59. PubMed ID: 7335762
    [No Abstract]   [Full Text] [Related]  

  • 14. Indobufen (K 3920), a new inhibitor of platelet aggregation: effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man.
    Tamassia V; Corvi G; Fuccella LM; Moro E; Tosolini G; Tremoli E
    Eur J Clin Pharmacol; 1979 Jun; 15(5):329-33. PubMed ID: 456404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of aspirin and indobufen in healthy volunteers.
    Lee JY; Sung KC; Choi HI
    Platelets; 2016; 27(2):105-9. PubMed ID: 26083594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of in vivo platelet aggregation by indobufen in angina patients during exercise.
    Pogliani EM; Fantasia R; Perini C; Corvi G
    J Int Med Res; 1981; 9(2):113-9. PubMed ID: 7014283
    [No Abstract]   [Full Text] [Related]  

  • 17. Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk.
    Mannucci L; Maderna P; Colli S; Lavezzari M; Sirtori CR; Tremoli E
    Thromb Res; 1987 Nov; 48(4):417-26. PubMed ID: 3445229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ticlopidine and indobufen on platelet aggregation induced by A23187 and adrenaline in the presence of different anticoagulants.
    Cimminiello C; Milani M; Uberti T; Arpaia G; Bonfardeci G
    J Int Med Res; 1989; 17(6):514-20. PubMed ID: 2516825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet activity and tolerance of indobufen (K3920) in cerebrovascular disease: a therapeutic approach.
    Carrieri P; Orefice G; La Pia S; Indaco A; D'Acunio F; Iadevaia V
    Pharmatherapeutica; 1983; 3(6):410-6. PubMed ID: 6353432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory activity of indobufen (*) on platelet aggregation in vivo.
    Bergamaschi M; Pierucci L; Branzoli U
    Pharmacol Res Commun; 1984 Oct; 16(10):979-85. PubMed ID: 6438651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.